ADRIATIC clinical trial results suggest durvalumab may offer a new path in small cell lung cancer care

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, its cost raises questions about sustainability, prevention and access.

Continue Reading

News Source: medicalxpress.com